Latest Articles
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - empr.com
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial empr.com
Published: July 31, 2026, 4 a.m.
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer - Seeking Alpha
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer Seeking Alpha
Published: July 30, 2026, 11:38 p.m.
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study - FirstWord Pharma
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study FirstWord Pharma
Published: July 30, 2026, 9:59 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - TipRanks
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint TipRanks
Published: July 30, 2026, 9:16 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - tipranks.com
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint tipranks.com
Published: July 30, 2026, 9:16 p.m.
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com - Investing.com Nigeria
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com Investing.com Nigeria
Published: July 30, 2026, 8:42 p.m.
Karyopharm endometrial cancer trial misses primary endpoint - Investing.com
Karyopharm endometrial cancer trial misses primary endpoint Investing.com
Published: July 30, 2026, 8:31 p.m.
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - Karyopharm
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer Karyopharm
Published: July 30, 2026, 8:09 p.m.
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - marketscreener.com
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer marketscreener.com
Published: July 30, 2026, 8:07 p.m.
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - PR Newswire
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer PR Newswire
Published: July 30, 2026, 8:05 p.m.
Link copied to clipboard!